Affiliation:
1. Petz Aladár Megyei Oktató Kórház Kardiológiai Osztály Győr Vasvári Pál út 2–4. 9024
Abstract
The choice of treatment of patients with hypertension should not be based solely on the blood pressure value, because the risk of cardiovascular diseases are influenced by the presence and magnitude of other risk factors, too. The presence of a metabolic disease (diabetes mellitus, metabolic syndrome) itself categorizes the patient as a high risk individual. In such cases the use of combined treatment is usually considered. For example, in case of hypertension aggraviated by left ventricular dysfunction, ischaemic heart disease or cardiac insufficiency, β-blocker treatment is usually included in the combination of the first setting. Orv. Hetil., 2015, 156(16), 623–625.
Reference16 articles.
1. Mancia, G., Fagard, R., Narkiewicz, K., et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J., 2013, 34(28), 2159–2219.
2. Kiss, I.: Professional and organizational guidelines of treatment of hypertension in adults and children. [A hypertoniabetegség felnőttkori és gyermekkori kezelésének szakmai és szervezeti irányelvei.] Hypertonia és Nephrologia, 2009, 13, 89–167. [Hungarian]
3. Shin, J. A., Lee, J. H., Lim, S. Y., et al.: Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J. Diabetes Investig., 2013, 4(4), 334–343.
4. Isomaa, B., Almgren, P., Tuomi, T., et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 2001, 24(4), 683–689.
5. Dézsi, C. A.: Differences in the clinical effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A critical review of the evidence. Am. J. Cardiovasc. Drugs, 2014, 14(3), 167–173.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献